Search Results
197 items found for "chronic kidney disease"
- 📰 GPCR Weekly News, June 17 to 23, 2024
grandiflora against Candida auris FKBP12 Development and therapeutic perspectives of CXCR4 antagonists for disease Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic
- GPR15 expressed in T lymphocytes from RA patients is involved in leukocyte chemotaxis to the...
Recent evidence indicates that GPR15 may be associated with modulation of the chronic inflammatory response
- New role of β-arrestins in MOR signaling
Morphine is one of the most widely used and proven analgesic for the treatment of severe acute or chronic Complex Persistent Opioid Dependence-an Opioid-induced Chronic Pain Syndrome.
- All Aboard the GPCR Express: Your Weekly Update is here! Oct 14-20, 2024
substitutions and recurrent gene loss in sauropsids Noval insights and therapeutic strategies for tumor-induced kidney
- 📰 GPCR Weekly News, July 24 to July 30, 2023
ion transients evoked by cell poking independently of released autocrine ATP in Madin-Darby canine kidney
- 📰 GPCR Weekly News, October 2 to 8, 2023
GPCR Function Interplay of Cholesterol and Actin in Neurotransmitter GPCR Signaling: Insights from Chronic
- 📰 GPCR Weekly News, April 24 to 30, 2023
Single cell G-protein coupled receptor profiling of Transcription factor 21 expressing activated kidney
- 📰 GPCR Weekly News, November 13 to 19, 2023
Butyrate induces STAT3/HIF-1α/IL-22 signaling via GPCR and HDAC3 inhibition to activate autophagy in head kidney
- Focusing on the role of secretin/adhesion (Class B) G protein-coupled receptors in placental...
high maternal mortality, is a risk factor highly associated with maternal and offspring cardiovascular disease Obesity, immunological diseases and endocrine metabolic diseases are high-risk factors for the development them, the secretin/adhesion (Class B) G protein-coupled receptors are essential drug targets for human diseases , such as endocrine diseases and cardiometabolic diseases.
- RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany...
monoclonal antibodies for the treatment of cancer, infections, metabolic disorders or inflammatory diseases Recently, functional autoantibodies targeting GPCRs have been associated with various disease-specific is to bring together the current knowledge on the role of autoantibodies targeting GPCRs in various diseases , such as cardiovascular diseases, renal diseases, autoimmune diseases such as systemic sclerosis or
- 📰 GPCR Weekly News, October 30 to November 4, 2023
Minor Effects on Cardiac Hypertrophy Single cell G-protein coupled receptor profiling of activated kidney
- 📰 GPCR Weekly News, March 18 to 24, 2024
Alexander Hauser, Caroline Gorvin et al. for their research on GPCR gene variants and human genetic disease of glycosaminoglycans in GPCR signaling G protein-coupled receptor-mediated autophagy in health and disease organelles Reviews, GPCRs, and more G protein-coupled receptor (GPCR) gene variants and human genetic disease Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
- Immunomodulatory Role of Neuropeptides in the Cornea
insights are made into the role of neuropeptides and their immunomodulatory functions in the healthy and diseased neuropeptides, receptor isoform-specific signaling events, and the inflammatory microenvironment in disease an increase in studies that have begun modulating neuropeptide activity for the treatment of corneal diseases focuses on the role of neuropeptides in maintaining the homeostasis of the ocular surface, alterations in disease
- G protein-coupled receptor kinase type 2 and β-arrestin2: Key players in immune cell functions...
GRK2/β-arrestin2 play multiple roles in the pathological mechanisms of a wide range of diseases including heart failure, cancer, and inflammatory diseases. cell function and focuses on the pathological implications of GRK2/β-arrestin2 in various inflammatory diseases
- Structures of oxysterol sensor EBI2/GPR183, a key regulator of the immune response
Aberrant EBI2 signaling is implicated in inflammatory bowel disease, sclerosis, and infectious disease oxysterol ligand and will facilitate the development of therapeutic approaches that target EBI2-linked diseases
- GPCRs Are Optimal Regulators of Complex Biological Systems and Orchestrate the Interface between ...
Are Optimal Regulators of Complex Biological Systems and Orchestrate the Interface between Health and Disease GPCRs arguably represent the most effective current therapeutic targets for a plethora of diseases The molecular diversity of GPCR signaling systems is likely to be closely associated with disease-associated complexity and compartmentalization, thus enabling a nuanced GPCR-based capacity to interdict multiple disease cellular activities implicates them as key controllers of the functional balance between health and disease
- GPCR Signaling and mTORC1 Regulation
The activation of mTOR complex 1 (mTORC1) is typically observed in human disease and continues to be Understanding the upstream regulators of mTORC1 will provide a crucial link to targeting mTORC1 hyperactivated diseases Statement mTORC1 is a master regulator of many cellular processes and is often hyperactivated in human disease molecular underpinnings of these pathways will undoubtedly be promising to the mTORC1 field and human disease
- VAMP2: a crucial player in the delivery of MOR to the synapse
dysfunction in the MOR-SNARE complex interaction can lead to various neurological disorders, such as chronic
- Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine..
Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases seven-transmembrane G-protein-coupled receptor (GPCR) involved in various pathologies, in particular autoimmune diseases
- 📰 GPCR Weekly News, July 31 to August 6, 2023
Nichola J Smith's investigation: Gene expression of TAS1R taste receptors for cardiometabolic disease Taste Gene expression analyses of TAS1R taste receptors relevant to the treatment of cardiometabolic disease GPCRs in Neuroscience Quinpirole ameliorates nigral dopaminergic neuron damage in Parkinson's disease development GPCRs in Oncology and Immunology GPCRs and fibroblast heterogeneity in fibroblast-associated diseases
- Crinetics Presents Clinical And Research Results At ENDO 2022
s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like
- Unlocking the Future of Medicine: Advancements in GPCR Research
regulation of beige adipocyte formation: Implications for obesity and metabolic health GPCRs in Neuroscience Chronic
- Structure of the human galanin receptor 2 bound to galanin and Gq reveals the basis of ligand...
coupled receptors (GPCRs) for galanin have been discovered, which is the focus of efforts to treat diseases including Alzheimer’s disease, anxiety, and addiction.
- A broad look into the future of systemic sclerosis
September 2022 "Systemic sclerosis (SSc) is a systemic autoimmune disease with the key features of inflammation Extracellular vesicles are another novel player to possess disease processes.
- Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of...
mechanistic computational approach that couples drug pharmacokinetics/pharmacodynamics and the course of disease It has begun to play important roles in drug development for complex diseases such as cancer, including
- 📰 GPCR Weekly News, June 24 to 30, 2024
Matthew Eddy , et al. for their investigation on Interaction Networks within Disease-Associated GαS receptor endocytosis generates spatiotemporal bias in β-arrestin signaling Interaction Networks within Disease-Associated Industry News Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases
- Ermium Therapeutics has constituted its SAB
international leaders in GPCRs pharmacology, immunology, drug discovery and development for auto-immune diseases
- Therapeutic validation of an orphan G protein‐coupled receptor
as sensory perception, reproduction, development, growth, metabolism, and are also linked to major diseases , such as neuroinflammatory, metabolic and autoimmune diseases. GPR84 has been additionally proposed to be a potential biomarker in different inflammatory diseases ( GPR84 is a promising target to exploit and the investment in better tools to study its function in both disease